



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

| | | | |
|----------------------------------------------------------|----------------------------------------|---------------------------------------|-------------------------|
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | Docket Number: 1662/607041 | |
| Application Number 10/759,906 | Filing Date January 16, 2004 | Examiner Not Yet Assigned | Art Unit 1614 |
| Invention Title Novel Synthesis of Irbesartan | | Inventors NISNEVICH, et al. | |

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop: _____
Commissioner for Patents, P.O. box 1450, Alexandria, VA 22313-1450

On

Date: 11/17/04

Signature: *Agnes Xu*
Agnes Xu

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 35 U.S.C. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. In accordance with the Official Gazette of August 5, 2003, which stated that the United States Patent and Trademark Office waived the requirement under 37 C.F.R. § 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. patent applications filed after June 30, 2003, copies of each of the cited U.S. patents and U.S. patent application publications are not being provided.
3. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.

4. Applicant's attorney certifies that each item of information contained in the information disclosure statement was first cited in the International Search Report (copy attached) from PCT office in a counterpart foreign application not more than three months prior to the filing of information disclosure statement.
5. It is believed that no fees are due in connection with this Supplemental Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 for such fees. A copy of this communication is enclosed for charging purposes.

Dated: *Mar 16, 2004*

By:


John B. Starr, Jr. (Reg. No. 44,474)

KENYON & KENYON
One Broadway
New York, New York 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)
CUSTOMER NUMBER 26646

| | | |
|-----------------------------------------------------------------------|------------------------------------------|--------------------------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449 | ATTY. DOCKET NO. 1662/607041 | U.S. SERIAL NO. 10/759,906 |
| | APPLICANT(S) NISNEVISH, et al. | |
| | FILING DATE January 16, 2004 | GROUP 1614 |



U. S. PATENT DOCUMENTS

| EXAMINER INITIAL | PATENT NUMBER | PATENT DATE | NAME | CLASS | SUBCLASS | FILING DATE |
|---------------------|------------------|----------------|-----------------|-------|----------|----------------|
| | USP 5,310,929 A | May 10, 1994 | Ardecky, et al. | | | |
| | USP 5,541,209 A | July 30, 1996 | Spinale, et al. | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|---------------------|--------------------|-------------------|---------|-------|----------|-------------|----|
| | | | | | | YES | NO |
| | GB 2 281 072 A | February 22, 1995 | UK | | | | |
| | EP 0 508 393 A | October 14, 1992 | EP | | | | |
| | EP 0 782 996 A | July 9, 1997 | EP | | | | |
| | FR 2 780 403 A | December 31, 1999 | France | | | | |
| | WO 2004/007482 A | January 22, 2004 | PCT | | | | |
| | WO 94/11012 A | May 26, 1994 | PCT | | | | |
| | | | | | | | |

OTHER DOCUMENTS

| EXAMINER INITIAL | AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC. |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | Murugesan, Natesan, et al., "Discovery Of N-Isoxazolyl Biphenylsulfonamides As Potent Dual Angiotensin II And Endothelin A Receptor Antagonists", <i>J. of Med. Chem.</i> (2002), 45(18), 3829-3835 |
| | Bernhart C.A., et al., "A New Series of Imidazolones: Highly Specific and Potent Nonpeptide AT ₁ Antiotensin II Receptor Antagonists", <i>J. of Med. Chem.</i> Vol. 36, no. 22, 1993, pp 3371-3380 |
| | |
| | |

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| EXAMINER | DATE CONSIDERED |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |